tradingkey.logo
tradingkey.logo
Search

Aquestive Therapeutics Inc

AQST
Add to Watchlist
3.695USD
-0.025-0.67%
Close 07-31 16:00ETQuotes delayed by 15 min
463.60MMarket Cap
LossP/E TTM

AQST Income Statement

You can find the annual or quarterly income statement of Aquestive Therapeutics Inc here for insights into the performance and operational efficiency of Aquestive Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
FY2019Q4
FY2019Q3
FY2019Q2
FY2019Q1
FY2018Q4
FY2018Q3
FY2018Q2
FY2018Q1
FY2017Q4
FY2017Q3
FY2017Q2
FY2017Q1
Total revenue
65.67%14.45M
9.67%13.02M
-5.43%12.81M
-50.23%10.00M
-27.65%8.72M
-10.14%11.87M
4.15%13.54M
51.79%20.10M
8.25%12.05M
23.63%13.21M
13.43%13.00M
-0.18%13.24M
-9.26%11.13M
-3.57%10.68M
-13.73%11.46M
-13.55%13.27M
10.32%12.27M
54.96%11.08M
60.86%13.29M
-29.20%15.35M
26.89%11.12M
-56.46%7.15M
-33.48%8.26M
94.76%21.68M
-30.67%8.77M
-2.41%16.42M
-6.40%12.42M
-20.10%11.13M
-46.00%12.64M
37.96%16.82M
-51.13%13.27M
25.00%13.93M
42.44%23.41M
--12.20M
--27.15M
--11.14M
--16.44M
Revenue
17.05%8.79M
11.34%11.98M
5.32%11.47M
8.16%8.79M
-28.58%7.51M
-2.15%10.76M
-4.57%10.89M
-30.19%8.12M
7.74%10.52M
15.63%11.00M
6.71%11.41M
-6.70%11.64M
-14.07%9.76M
-9.25%9.51M
-14.02%10.69M
-0.84%12.47M
36.50%11.36M
64.21%10.48M
63.83%12.44M
48.31%12.58M
3.06%8.32M
-56.53%6.38M
-24.01%7.59M
-12.44%8.48M
11.38%8.08M
76.93%14.68M
10.93%9.99M
11.54%9.69M
-37.28%7.25M
-21.58%8.30M
-0.17%9.01M
-15.98%8.68M
13.84%11.56M
--10.58M
--9.02M
--10.34M
--10.15M
Cost of revenue
-5.01%3.47M
29.12%5.84M
1.56%4.51M
0.77%4.56M
-16.79%3.65M
-3.40%4.52M
-7.52%4.44M
-31.60%4.53M
-7.35%4.39M
-11.80%4.68M
3.74%4.80M
26.23%6.62M
12.41%4.74M
57.61%5.30M
5.11%4.63M
17.38%5.24M
52.85%4.21M
20.73%3.37M
47.75%4.40M
26.19%4.47M
-24.65%2.76M
-58.95%2.79M
-35.86%2.98M
-34.70%3.54M
4.36%3.66M
41.88%6.79M
-16.97%4.64M
8.99%5.42M
-37.79%3.51M
-14.75%4.79M
14.59%5.59M
-3.27%4.97M
34.70%5.64M
--5.62M
--4.88M
--5.14M
--4.18M
Operating expenses
-33.59%18.65M
64.48%41.85M
11.24%24.29M
6.62%21.37M
33.67%28.09M
48.66%25.45M
41.96%21.83M
14.87%20.04M
33.49%21.01M
-20.00%17.12M
-24.30%15.38M
-32.95%17.45M
-28.49%15.74M
-5.94%21.39M
-4.42%20.32M
19.05%26.03M
12.02%22.01M
-0.21%22.75M
-3.57%21.25M
2.73%21.86M
-13.17%19.65M
-13.40%22.80M
-5.89%22.04M
-28.63%21.28M
-12.02%22.63M
-9.77%26.32M
4.22%23.42M
-36.03%29.82M
42.04%25.72M
49.98%29.17M
34.36%22.47M
206.65%46.61M
15.66%18.11M
--19.45M
--16.73M
--15.20M
--15.65M
R&D expenses
-21.58%4.20M
-35.00%3.20M
-14.03%4.53M
-1.37%4.11M
-9.63%5.36M
70.26%4.92M
64.86%5.27M
19.84%4.16M
67.24%5.93M
-32.49%2.89M
-1.11%3.20M
-33.19%3.47M
-25.69%3.55M
-2.77%4.28M
-31.61%3.23M
21.96%5.20M
30.45%4.77M
-0.56%4.40M
-34.90%4.73M
10.79%4.26M
-15.96%3.66M
44.75%4.42M
43.39%7.26M
-52.80%3.85M
1.19%4.35M
-46.21%3.06M
11.67%5.06M
1.96%8.15M
-12.20%4.30M
-9.38%5.68M
-20.23%4.53M
65.27%7.99M
-20.02%4.90M
--6.27M
--5.68M
--4.84M
--6.13M
Depreciation, depletion, and amortization
-18.71%113.00K
-11.56%130.00K
-12.58%139.00K
-31.71%140.00K
-32.85%139.00K
-68.52%147.00K
-39.77%159.00K
-29.07%205.00K
-36.31%207.00K
17.63%467.00K
-55.70%264.00K
-56.67%289.00K
-55.30%325.00K
-45.69%397.00K
-19.13%596.00K
-10.11%667.00K
-3.84%727.00K
-42.80%731.00K
1.38%737.00K
4.21%742.00K
3.99%756.00K
65.12%1.28M
2.54%727.00K
-1.66%712.00K
-2.94%727.00K
1.84%774.00K
-4.96%709.00K
-6.82%724.00K
-21.41%749.00K
-21.41%760.00K
-22.05%746.00K
-18.12%777.00K
2.69%953.00K
--967.00K
--957.00K
--949.00K
--928.00K
Operating profit
78.29%-4.20M
-112.38%-28.84M
-38.47%-11.48M
-20769.09%-11.37M
-116.20%-19.36M
-247.20%-13.58M
-248.76%-8.29M
101.31%55.00K
-94.51%-8.96M
63.49%-3.91M
73.15%-2.38M
67.02%-4.21M
52.71%-4.61M
8.19%-10.71M
-11.11%-8.85M
-95.83%-12.76M
-14.23%-9.74M
25.42%-11.67M
42.18%-7.97M
-1749.87%-6.52M
38.50%-8.53M
-57.98%-15.65M
-25.26%-13.78M
102.11%395.00K
-6.02%-13.86M
19.80%-9.90M
-19.53%-11.00M
42.83%-18.69M
-346.45%-13.07M
-70.19%-12.35M
-188.32%-9.20M
-705.27%-32.69M
579.26%5.30M
---7.26M
--10.42M
---4.06M
--781.00K
Net non-operating interest income (expenses)
Non-operating interest income
-88.36%83.00K
70.57%1.25M
-68.74%306.00K
50.25%2.10M
116.72%713.00K
344.85%734.00K
-35.34%979.00K
981.40%1.40M
-97.73%329.00K
153.85%165.00K
30180.00%1.51M
303.13%129.00K
--14.51M
-51.85%65.00K
--5.00K
-91.42%32.00K
----
3275.00%135.00K
----
1972.22%373.00K
----
-94.37%4.00K
-94.20%8.00K
-88.24%18.00K
-62.77%102.00K
-77.39%71.00K
-36.11%138.00K
--153.00K
--274.00K
--314.00K
--216.00K
----
----
----
--0.00
----
----
Non-operating interest expense
6.51%2.96M
2.20%2.84M
2.16%2.84M
0.07%2.78M
-0.07%2.78M
22.26%2.78M
121.34%2.78M
102.40%2.78M
94.01%2.78M
37.76%2.27M
-23.83%1.26M
-16.02%1.37M
-11.47%1.44M
-5.39%1.65M
-41.52%1.65M
-40.70%1.64M
-42.37%1.62M
-36.99%1.74M
1.51%2.82M
0.36%2.76M
1.52%2.81M
-1.25%2.77M
4.75%2.78M
41.82%2.75M
43.87%2.77M
47.37%2.80M
37.20%2.65M
0.52%1.94M
-0.05%1.93M
-3.45%1.90M
-1.88%1.93M
-1.13%1.93M
6.00%1.93M
--1.97M
--1.97M
--1.95M
--1.82M
Gains from sale of securities
34.96%-973.00K
0.83%-1.43M
-1.06%-1.43M
-5.58%-1.50M
-5.65%-1.50M
-50.21%-1.45M
-2432.14%-1.42M
-2474.55%-1.42M
-2623.08%-1.42M
-1681.48%-962.00K
97.25%-56.00K
97.16%-55.00K
97.21%-52.00K
97.07%-54.00K
45.87%-2.04M
44.11%-1.94M
44.18%-1.86M
5.77%-1.84M
---3.77M
---3.47M
---3.33M
---1.96M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Special income (expenses)
----
----
----
----
----
100.00%0.00
--0.00
--0.00
100.00%0.00
---1.03M
--0.00
--0.00
---353.00K
100.00%0.00
----
----
----
---13.82M
----
----
----
--0.00
100.00%0.00
----
----
--0.00
-18.95%-4.90M
100.00%0.00
-100.00%0.00
100.00%0.00
---4.12M
-1774.77%-1.86M
265.95%697.00K
---814.00K
--0.00
--111.00K
---420.00K
Other non-operating income (expenses)
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
---7.00K
---1.00K
---21.00K
--24.00K
--0.00
--0.00
--0.00
--0.00
Income before tax
64.86%-8.06M
-86.65%-31.86M
-34.21%-15.45M
-393.55%-13.55M
-78.75%-22.93M
-113.10%-17.07M
-429.15%-11.51M
50.16%-2.75M
-259.00%-12.83M
35.15%-8.01M
82.65%-2.17M
66.21%-5.51M
161.03%8.07M
57.33%-12.35M
13.87%-12.54M
-31.82%-16.30M
9.90%-13.22M
-42.11%-28.95M
12.06%-14.55M
-429.86%-12.37M
11.24%-14.67M
-61.19%-20.37M
10.11%-16.55M
88.60%-2.33M
-12.25%-16.53M
9.38%-12.64M
-22.44%-18.41M
43.90%-20.47M
-459.26%-14.73M
-38.88%-13.94M
-277.94%-15.04M
-518.84%-36.49M
381.33%4.10M
---10.04M
--8.45M
---5.90M
---1.46M
Income tax
--0.00
100.00%0.00
--0.00
--0.00
--0.00
-113.86%-14.00K
100.00%0.00
-100.00%0.00
--0.00
--101.00K
---140.00K
--284.00K
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Income after tax
64.86%-8.06M
-86.81%-31.86M
-34.21%-15.45M
-393.55%-13.55M
-78.75%-22.93M
-110.27%-17.05M
-465.55%-11.51M
52.61%-2.75M
-259.00%-12.83M
34.33%-8.11M
83.77%-2.04M
64.47%-5.79M
161.03%8.07M
57.33%-12.35M
13.87%-12.54M
-31.82%-16.30M
9.90%-13.22M
-42.11%-28.95M
12.06%-14.55M
-429.86%-12.37M
11.24%-14.67M
-61.19%-20.37M
10.11%-16.55M
88.60%-2.33M
-12.25%-16.53M
9.38%-12.64M
-22.44%-18.41M
43.90%-20.47M
-459.26%-14.73M
-38.88%-13.94M
-277.94%-15.04M
-518.84%-36.49M
381.33%4.10M
---10.04M
--8.45M
---5.90M
---1.46M
Net income from continuous operations
64.86%-8.06M
-86.81%-31.86M
-34.21%-15.45M
-393.55%-13.55M
-78.75%-22.93M
-110.27%-17.05M
-465.55%-11.51M
52.61%-2.75M
-259.00%-12.83M
34.33%-8.11M
83.77%-2.04M
64.47%-5.79M
161.03%8.07M
57.33%-12.35M
13.87%-12.54M
-31.82%-16.30M
9.90%-13.22M
-42.11%-28.95M
12.06%-14.55M
-429.86%-12.37M
11.24%-14.67M
-61.19%-20.37M
10.11%-16.55M
88.60%-2.33M
-12.25%-16.53M
9.38%-12.64M
-22.44%-18.41M
43.90%-20.47M
-459.26%-14.73M
-38.88%-13.94M
-277.94%-15.04M
-518.84%-36.49M
381.33%4.10M
---10.04M
--8.45M
---5.90M
---1.46M
Net income attributable to controlling interests
64.86%-8.06M
-86.81%-31.86M
-34.21%-15.45M
-393.55%-13.55M
-78.75%-22.93M
-110.27%-17.05M
-465.55%-11.51M
52.61%-2.75M
-259.00%-12.83M
34.33%-8.11M
83.77%-2.04M
64.47%-5.79M
161.03%8.07M
57.33%-12.35M
13.87%-12.54M
-31.82%-16.30M
9.90%-13.22M
-42.11%-28.95M
12.06%-14.55M
-429.86%-12.37M
11.24%-14.67M
-61.19%-20.37M
10.11%-16.55M
88.60%-2.33M
-12.25%-16.53M
9.38%-12.64M
-22.44%-18.41M
43.90%-20.47M
-459.26%-14.73M
-30.73%-13.94M
-292.18%-15.04M
-460.40%-36.49M
298.02%4.10M
---10.67M
--7.83M
---6.51M
---2.07M
Preferred share dividend
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--626.00K
--626.00K
--615.00K
--613.00K
Net income attributable to common shareholders
64.86%-8.06M
-86.81%-31.86M
-34.21%-15.45M
-393.55%-13.55M
-78.75%-22.93M
-110.27%-17.05M
-465.55%-11.51M
52.61%-2.75M
-259.00%-12.83M
34.33%-8.11M
83.77%-2.04M
64.47%-5.79M
161.03%8.07M
57.33%-12.35M
13.87%-12.54M
-31.82%-16.30M
9.90%-13.22M
-42.11%-28.95M
12.06%-14.55M
-429.86%-12.37M
11.24%-14.67M
-61.19%-20.37M
10.11%-16.55M
88.60%-2.33M
-12.25%-16.53M
9.38%-12.64M
-22.44%-18.41M
43.90%-20.47M
-459.26%-14.73M
-30.73%-13.94M
-292.18%-15.04M
-460.40%-36.49M
298.02%4.10M
---10.67M
--7.83M
---6.51M
---2.07M
Basic earnings per share
72.63%-0.07
-39.54%-0.26
-10.54%-0.14
-351.81%-0.14
-37.79%-0.24
-55.03%-0.19
-301.65%-0.13
70.11%-0.03
-220.16%-0.17
46.84%-0.12
86.59%-0.03
71.84%-0.10
145.49%0.15
68.33%-0.23
36.76%-0.23
-7.47%-0.36
22.72%-0.32
-18.94%-0.72
24.63%-0.37
-380.14%-0.33
16.22%-0.41
-26.03%-0.60
33.07%-0.49
91.52%-0.07
16.53%-0.49
14.70%-0.48
-15.66%-0.74
56.91%-0.82
-452.58%-0.59
-28.66%-0.56
-299.12%-0.64
-615.50%-1.90
298.02%0.17
---0.44
--0.32
---0.27
---0.08
Diluted earnings per share
72.63%-0.07
-39.54%-0.26
-10.54%-0.14
-351.81%-0.14
-37.79%-0.24
-55.03%-0.19
-301.65%-0.13
70.11%-0.03
-259.39%-0.17
46.84%-0.12
86.59%-0.03
71.84%-0.10
134.29%0.11
68.33%-0.23
36.76%-0.23
-7.47%-0.36
22.72%-0.32
-18.94%-0.72
24.63%-0.37
-380.14%-0.33
16.22%-0.41
-26.03%-0.60
33.07%-0.49
91.52%-0.07
16.53%-0.49
14.70%-0.48
-15.66%-0.74
56.91%-0.82
-452.58%-0.59
-28.66%-0.56
-299.12%-0.64
-615.50%-1.90
298.02%0.17
---0.44
--0.32
---0.27
---0.08
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Aquestive Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing AQST stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Aquestive Therapeutics Inc's revenue at year end?

Aquestive Therapeutics Inc reported 44.55M in revenue for fiscal year 2025, up from 57.56M in the previous year.

How much revenue did Aquestive Therapeutics Inc report in the most recent quarter?

Aquestive Therapeutics Inc reported 14.45M in revenue for the most recent quarter, an increase of 65.67% year over year.

What was Aquestive Therapeutics Inc's net income for the year?

Aquestive Therapeutics Inc posted -83.78M in net income for fiscal year 2025.

How much net income did Aquestive Therapeutics Inc post in the last quarter?

Aquestive Therapeutics Inc reported -8.06M in net income for the latest quarter。

What was Aquestive Therapeutics Inc's annual operating profit?

Aquestive Therapeutics Inc's operating income was -71.05M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.